Compositions and methods for inhibiting expression of the MYC gene
View Patent ↗The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the MYC gene (MYC gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the MYC gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by MYC gene expression and the expression of the MYC gene using the pharmaceutical composition.
1. A double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a human MYC gene, wherein said dsRNA comprises a sense strand and an antisense strand, wherein the sense strand consists of the nucleotide sequence of SEQ ID NO:11 and the antisense strand consists of the nucleotide sequence of SEQ ID NO:12 and each strand is modified as follows to include a 2′-O-methyl ribonucleotide as indicated by a lower case letter “c” or “u” and a phosphorothioate as indicated by a lower case letter “s”:
SEQ ID NO:11 is cGAcGAGAAcAGuuGAAAcTsT and
SEQ ID NO:12 is GUUUcAACUGUUCUCGUCGTsT.
2. A cell comprising the dsRNA of claim 1 .
3. A pharmaceutical composition for inhibiting the expression of the MYC gene, comprising the dsRNA of claim 1 and a pharmaceutically acceptable carrier.
4. An in-vitro method for inhibiting the expression of the MYC gene in a cell, the method comprising:
(a) introducing into the cell the dsRNA of claim 1 ; and
(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of the MYC gene, thereby inhibiting expression of the MYC gene in the cell.
5. A vector for inhibiting the expression of the MYC gene, said vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes at least one strand of the dsRNA of claim 1 .
6. A cell comprising the vector of claim 4 .
7. A method of treating breast cancer comprising administering to a patient in need of such treatment, a therapeutically effective amount of the dsRNA of claim 1 .
8. The pharmaceutical composition of claim 3 , wherein the carrier is lipid carrier.